Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.88
- Piotroski Score 2.00
- Grade Buy
- Symbol (OVID)
- Company Ovid Therapeutics Inc.
- Price $1.15
- Changes Percentage (1.77%)
- Change $0.02
- Day Low $1.11
- Day High $1.18
- Year High $4.10
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/01/2024
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $11.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.72
- Trailing P/E Ratio -4.11
- Forward P/E Ratio -4.11
- P/E Growth -4.11
- Net Income $-52,338,959
Income Statement
Quarterly
Annual
Latest News of OVID
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Savings interest rates today, October 5, 2024 (best account provides 5.25% APY)
Savings account interest rates have recently dropped after the Federal Reserve cut its target rate in September. Despite this, many high-yield savings accounts still offer competitive rates, with some...
By Yahoo! Finance | 1 day ago -
CD rates today, October 5, 2024 (best account provides 4.32% APY)
CD interest rates are currently high due to recent Federal Reserve rate hikes, but a rate cut may be imminent. Ensure you find the best CD rates for your investment. Shorter-term CDs now offer better ...
By Yahoo! Finance | 1 day ago -
California vineyard owner says he was fined $120K for providing free housing to his employee
A vineyard owner in California is suing Santa Clara County for over $120,000 in fines for letting his employee live in an RV on his property. The county claims it's a zoning violation, but the owner a...
By AP NEWS | 1 day ago